OQROGet OQRO Pro
Insider trade

Cocrystal Pharma (COCP)Director bought ~$20K

FROST PHILLIP MD ET AL, Director at Cocrystal Pharma, bought ~$20K of Cocrystal Pharma shares.

~$20K
Approx. value · 20K sh @ $0.9976
1.91M
Holds after · shares reported
Traded
Feb 24, 2026
Filed
Feb 25, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Dec 24, 2025InsiderDirector purchased ~$24K of COCP shares in the open market
  2. Dec 26, 2025Insider · 14 days before an 8-KDirector purchased ~$39K of COCP shares in the open market
  3. Dec 30, 2025Insider · 10 days before an 8-KDirector purchased ~$19K of COCP shares in the open market
  4. Dec 31, 2025Insider · 9 days before an 8-KDirector purchased ~$47K of COCP shares in the open market
  5. Jan 9, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On January 9, 2026, the Compensation Committee (the “Committee”) of the Board of Directors of Cocrystal Pharma, Inc. (the “Company”) approved the grant of non-qualified stock options to the Company’s directors, executive officers and a certain consultant.”
  6. Feb 6, 2026InsiderDirector purchased ~$47K of COCP shares in the open market
  7. Feb 24, 2026 · this disclosureInsider · 14 days before an 8-KDirector purchased ~$20K of COCP shares in the open market

What came next

  1. Mar 10, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“Cocrystal Pharma, Inc. (the “Company”) sadly learned on March 10, 2026 that Dr. Anthony Japour, a member of the Company’s board of directors, passed away.”
  2. Mar 31, 2026Company filing · Form 8-K · ResultsReported its results
  3. Jun 3, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On June 3, 2026, the Board of Directors (the “Board”) of Cocrystal Pharma, Inc. (the “Company”) appointed James Sapirstein as the Chief Executive Officer of the Company, effective immediately, pursuant to the terms of an employment offer letter (the “Offer Letter”).”
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Cocrystal Pharma

For Cocrystal Pharma, OQRO holds 2 insider filings (SEC Form 4 or Form 144) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its COCP page.

Other recent filings by FROST PHILLIP MD ET AL, Director

The full history of FROST PHILLIP MD ET AL, Director is on the profile page.

How this filing works

Other disclosures at Cocrystal Pharma

Everything OQRO holds on this company is on its COCP page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Unlock OQRO ProAlready have an account? Log in

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data